Protein degradation therapies work by exploiting the ubiquitin-proteasome system, the cell’s built-in recycling network. In this process, enzymes known as E3 ligases attach molecular tags called ubiquitin to selected proteins. Once tagged, the proteins are transported to the proteasome, a cellular structure that breaks them down. Molecular glue degraders do not simply block a protein’s activity. Instead, they bring an E3 ligase into contact with a previously unrelated cellular protein, effectively redirecting the ligase so that the target is marked for destruction.

The concept has already transformed thinking about proteins considered difficult or impossible to inhibit with conventional drugs. In 2014, Benjamin Ebert, MD, PhD, president and CEO of Dana-Farber, helped establish that lenalidomide, a multiple myeloma treatment, works by acting as a molecular glue degrader of a transcription factor. Transcription factors often lack the deep binding pockets required for traditional inhibitors, leading researchers to describe them as “undruggable.” Their destruction through induced protein-protein interactions demonstrated that drug discovery could target the presence of a protein rather than merely interfere with its function.

Despite the promise of the technology, currently developed protein degraders rely on only a small fraction of the approximately 600 E3 ligases encoded by the human genome. Dana-Farber’s new platform is designed to explore this largely untapped biological diversity. The system begins by attaching selected E3 ligases to magnetic beads in laboratory wells. Researchers then expose the immobilized enzymes to cellular lysate, which contains the broad mixture of proteins found inside cells, together with a library of chemical compounds.

A compound is considered a potential hit when it binds to an E3 ligase and increases the ligase’s affinity for another protein in the cellular mixture. This induced proximity can cause the recruited protein to accumulate around the drug-bound ligase, creating the molecular arrangement required for degradation. The researchers used mass spectrometry to identify the proteins associated with each ligase-compound combination. This allowed them to determine which cellular proteins might be recruited and tagged for destruction after the complex was introduced into living cells.

The team tested the discovery system against seven E3 ligases and identified an interaction between the protein DDX18 and DCAF11, an understudied member of the E3 ligase family. By progressively narrowing the chemical library, the researchers traced the activity to a compound known as M12. The result initially appeared to offer a straightforward example of a new molecular glue degrader. However, when the investigators attempted to use M12 in cells to eliminate DDX18, the compound failed to produce the expected degradation.

That unexpected failure led the researchers to examine the molecular complex in greater detail. Using cryo-electron microscopy, co-first author Franziska Wachter, MD, and colleagues determined that M12 had undergone a chemical alteration called glutathionylation. This process involves the attachment of glutathione, a small molecule involved in maintaining cellular redox balance, to another molecule or protein. The modification changed M12 into its active form, explaining why the original compound behaved differently in the test tube and in living cells.

The finding suggests that molecular glues may be regulated by the metabolic state of a cell rather than functioning as permanently active compounds. M12 became effective in cells with elevated levels of metabolites associated with oxidative stress, a condition frequently observed in cancer cells because of their altered metabolism, rapid proliferation and demanding growth environment. In principle, this type of activation could allow future degraders to operate preferentially in diseased cells while remaining less active in normal tissue, although extensive research will be required to determine whether such selectivity can be converted into a safe medicine.

Further experiments showed that activated M12 was not restricted to DDX18. By modifying the proteins recruited to the DCAF11 complex, the researchers were able to direct degradation toward several additional targets, including SMARCA2, WEE1 and CDK7, all of which have important roles in cancer biology. The results represent a proof of principle for a scalable discovery strategy rather than the identification of a finished drug candidate. Nevertheless, the work demonstrates how combining chemical screening, proteomics, structural biology and cell-based testing can reveal unexpected forms of degrader activity. Eric Fischer, PhD, and Ebert said the platform could accelerate the discovery of molecular glues that expand the range of cancer-related proteins accessible to therapeutic degradation.

Subject of Research: Systematic discovery of molecular glue degraders and metabolically activated protein degradation for cancer therapy.

News Publication Date: 6-Aug-2026

Web References: Dana-Farber Cancer Institute: https://www.dana-farber.org/ ; Eric Fischer, PhD: https://www.dana-farber.org/find-a-doctor/eric-fischer ; Benjamin Ebert, MD, PhD: https://www.dana-farber.org/find-a-doctor/benjamin-levine-ebert ; Franziska Wachter, MD: https://www.dana-farber.org/find-a-doctor/franziska-wachter

References: Nature, article publication date 5-Aug-2026.

Keywords: molecular glue degraders, targeted protein degradation, E3 ligases, DCAF11, DDX18, M12, glutathionylation, oxidative stress, cancer drug discovery, cryo-electron microscopy, proteomics, molecular biology

The pivotal insight into the design of these novel PROTACs emerged from a co-crystal structure analysis of a known bivalent PROTAC, MZ1. This molecular complex revealed how the interaction between the ligands and their respective targets is mediated by spatial arrangements which can be manipulated to increase valency. By employing macrocyclic structures, researchers aim to attain a more rigid and defined bioactive conformation, which consequently enhances the overall stability and function of the PROTAC. On the other hand, the trivalent PROTACs take a different approach, focusing on increasing the avidity and cooperativity of the PROTAC ternary complex by augmenting the number of binding sites available for the target protein.

The synthesis of these innovative PROTACs, dubbed macroPROTAC-1 and SIM1, follows a rigorous, step-by-step botanical approach. Researchers outline a well-planned synthetic pathway that not only details the generation of the macrocyclic and trivalent cores but also explores the precise conjugation methods to their respective ligands. This elaborate synthesis procedure emphasizes the necessity of maintaining precise control over the molecular architecture to ensure functional integrity.

The synthesis of macroPROTAC-1 is anticipated to be a 14-day endeavor, while the construction of SIM1 is predicted to take around 10 days. This meticulous timeframe underscores the complexity of the processes involved in creating these compounds, showcasing the advanced techniques that underpin modern chemistry. As researchers embark on this journey, they are met with numerous challenges that test their knowledge of organic chemistry, reaction mechanisms, and biophysical methods for characterizing the resulting molecules.

In addition to the synthesis, an integral aspect of the development process involves the biophysical and cellular evaluation of these next-generation PROTACs. This includes assessing how well each compound binds to its target and E3 ligase, as well as testing their efficacy in promoting protein degradation in living cells. Such evaluations are fundamental, as they provide crucial insights into the practicality and therapeutic potential of these molecules. Preliminary results suggest that the macrocyclic and trivalent designs confer advantages over traditional PROTACs, indicating improved specificity and reduced off-target effects.

Moreover, by employing rigorous negative control compounds, researchers can better assess the performance of macroPROTAC-1 and SIM1. These controls serve as benchmarks, illuminating the distinct advantages of the new designs and providing a comparative analysis that is essential for validating scientific rigor. This methodical approach exemplifies how innovative research can redefine existing boundaries in drug design and development, opening doors for effective therapeutic strategies against previously difficult-to-treat diseases.

The findings stemming from these proof-of-concept studies demonstrate not only the viability of more complex molecular constructs but also their potential to address unmet medical needs in various therapeutic areas. The rapid expansion of the PROTAC platform underscores a shift in chemical biology, encouraging novel explorations in ligand development, connectivity, and stability. As current studies evolve, it becomes increasingly clear that expanding beyond traditional approaches is essential for harnessing the full power of targeted protein degradation.

As the research community continues to delve into the synthesis and application of macrocyclic and trivalent PROTACs, the implications extend far beyond cancer treatment. Future applications may emerge across various other diseases, including neurodegenerative conditions and autoimmune disorders, as scientists better understand the intricacies of protein interactions and degradation pathways. The evolution of PROTAC technology promises a transformative legacy in the realm of medicinal chemistry that could lead to breakthroughs in our quest for precision medicine.

Innovations like macroPROTAC-1 and SIM1 exemplify how creativity in chemical design is unlocking new potentials. This journey of discovery integrates traditional synthetic methodologies with cutting-edge biophysical techniques, fostering an environment ripe for innovation. As researchers remain committed to pushing the boundaries of what is possible, the realm of targeted protein degradation stands on the cusp of a new era—one marked by comprehensive therapeutic options and improved quality of life for patients facing formidable health challenges.

Ultimately, the future of PROTAC research is not just about refining compounds but also about understanding the underlying mechanisms that will aid in creating next-generation therapies. As new discoveries emerge, they will not only enrich the scientific literature but will also pave the way for a more nuanced approach to drug design. The ongoing journey into the realm of macrocyclic and trivalent PROTACs will surely inspire future generations of scientists to challenge the status quo and explore the uncharted territories of biochemical innovation.

Technology-driven collaborations across academic and industry spheres will further amplify the efforts to translate these discoveries into therapeutic realities. The synthesis process of compounds like macroPROTAC-1 and SIM1 highlights the importance of interdisciplinary research, bringing together expertise in organic chemistry, structural biology, and pharmacology. This collaboration will likely accelerate the transition from concept to clinical application, ensuring that the potential of targeted protein degradation is fully realized in therapeutic settings.

As this pioneering research unfolds, it captures the spirit of modern scientific inquiry, emphasizing the importance of adaptability, creativity, and tenacity. In a landscape characterized by rapid advancement, the development of novel PROTACs presents a compelling case study in the convergence of science, innovation, and clinical need—ultimately illustrating how far we can go when science and creativity intersect.

In conclusion, the innovative approach to designing macrocyclic and trivalent PROTACs signifies a transformative advancement in therapeutic strategies. With a clear focus on synthetic methodology, structure-function relationships, and experimental validation, researchers are charting a promising course toward revolutionizing drug discovery and development. These efforts mark a decisive moment in the ongoing fight against disease, heralding a new age of precision therapy characterized by targeted actions and minimized side effects.

Through diligent research and collaborative efforts, the potential for macrocyclic and trivalent PROTACs to change the landscape of medicine is indeed on the horizon, promising not only to enhance our understanding of protein biology but also to improve patient outcomes in tangible, meaningful ways.

Subject of Research: Macrocyclic and Trivalent PROTACs

Article Title: Branching beyond bifunctional linkers: synthesis of macrocyclic and trivalent PROTACs

Article References:

Cao, Y., Harris, A.L. & Ciulli, A. Branching beyond bifunctional linkers: synthesis of macrocyclic and trivalent PROTACs.
Nat Protoc (2025). https://doi.org/10.1038/s41596-025-01283-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41596-025-01283-0

Keywords: PROTACs, Macrocyclic, Trivalent, Targeted Protein Degradation, Drug Development.